An Observational Follow-up Study to Describe Treatment Patterns and Outcomes in Hepatitis B Patients With HBsAg Decline in Past 6 Months

What this Trial Is About

This observational study follows adults with chronic hepatitis B who have experienced a decline in HBsAg levels within the past 12 months. The research aims to describe treatment patterns and assess their impact on HBsAg loss, regardless of whether new molecular entity therapies were used. Participants will be monitored over 36 months, with possible extensions depending on study goals. Patients continue receiving treatment or no treatment based on routine clinical care determined by their physicians. This non-interventional study records medical decisions, treatments, and data without influencing patient care. Follow-up visits occur regularly, typically twice a year or more frequently during specific therapies, and retrospective data from prior visits may also be included. Participants will undergo evaluations including blood sample collection for HBV markers and immune response tests. Researchers will track HBsAg loss at 12 months as the primary outcome, along with other measures over time such as seroconversion rates, liver complications, and quality of life. The study involves ongoing documentation and monitoring aligned with clinical practice, with total participation lasting up to three years or longer.

HBsAg Declined Patients Follow-up Study